NCT06200974Recruiting
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
Multi-omic Approach to Study High Dose Rate (HDR) Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
Source: ClinicalTrials.gov · Last updated 2 Feb 2026
Brief summary (registry, in English)
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy. This study takes a multi-omics approach to study the mechanism of action of HDR brachytherapy through metabolomics, immunological, transcriptomics, and spectroscopic profiling. The results of this study will clarify the optimal dose for HDR prostate brachytherapy by documenting the dose-response relationship seen in the changing tumor metabolites after HDR brachytherapy and investigate the immunogenicity of HDR brachytherapy.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 13 Dec 2023
- Start date
- 1 Feb 2024
- Primary completion date
- 1 Mar 2028
- Lead sponsor
- British Columbia Cancer Agency
- Diseases
- Prostate cancer
- NCT number
- NCT06200974
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Feb 2024 to the primary completion date, 1 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior radical surgery for carcinoma of the prostate,
- Prior pelvic radiation
- Prior chemotherapy for prostate cancer,
Other illness
- Patients unsuitable for general anesthesia, on blood thinners which cannot be stopped for 24 hours, or who have contraindications to radiotherapy such as systemic sclerosis, or inflammatory bowel disease
Other
- Claustrophobic or unable to undergo MRI
Who the study is looking for
- Favorable risk and intermediate-risk prostate cancer with estimated life expectancy of at least 10 years.
- Clinical stage T1c-T2b, PSA \< 20, Gleason \< 8
- ECOG 0-1
- Low tier intermediate-risk prostate cancer is defined by: a single NCCN intermediate risk factor (either Gleason 7(3+4) and PSA \< 10 ng/ml OR Gleason 6 and PSA 10-20 ng/ml)
- Extensive favorable-risk disease is defined as: clinical stage T1c-T2a, PSA \< 10, Gleason 6, ≥ 50% of biopsy cores containing cancer, PSA density \> 0.2 ng/cc,
- Selected intermediate risk patients not defined above
- T1c/T2a
- PSA \< 10 and Gleason 4+3
- PSA \> 10 (\< 20) and Gleason 3+4
- PSA 10-15 ng/ml and Gleason 4+3 and \< 33% cores involved
- Max tumor length in any core 10 mm
- No androgen deprivation therapy (ADT)
- Signed study specific informed consent.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| British Columbia Cancer Center for the Southern Interior Coordinator of this site? Confirm its status | Kelowna | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.